CompletedNCT06023160
Predicting Functional Outcome and Response to Therapy of Anti-NMDAR Encephalitis at Diagnosis
Studying Encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Erasmus Medical Center
- Principal Investigator
- Maarten J. Titulaer, Assoc. Porf.Erasmus Medical Center
- Enrollment
- 714 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2024
Study locations (1)
- Erasmus Medical Center, Rotterdam, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06023160 on ClinicalTrials.govOther trials for Encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07511049Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot StudyNational Institute of Neurological Disorders and Stroke (NINDS)
- ACTIVE NOT RECRUITINGNCT07554261Clinical Features and Outcomes of VZV CNS InfectionsKocaeli University
- RECRUITINGNCT07332234Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral PathologiesSpitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
- ACTIVE NOT RECRUITINGNCT06820060Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel PlusQIAGEN Gaithersburg, Inc
- ACTIVE NOT RECRUITINGPHASE2NCT06899802A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineBavarian Nordic
- RECRUITINGPHASE1, PHASE2NCT06680128A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsSK Bioscience Co., Ltd.
- RECRUITINGNCT06368648CoMind Early Feasibility StudyCoMind Technologies Limited
- ACTIVE NOT RECRUITINGPHASE4NCT06678373Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasLiaoning Chengda Biotechnology CO., LTD